SCHEMBL290401

SCHEMBL290401

O=C(O)NCc1cnc(Br)s1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FPR2 P25090 2/20 0.44
FPR3 P25089 1/20 0.40
HDAC6 Q9UBN7 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.35
CYP1A2 P05177 1/20 0.33
CYP2D6 P10635 1/20 0.33
CYP2C9 P11712 1/20 0.33
TSHR P16473 1/20 0.33
CYP2C19 P33261 1/20 0.33
MAPK1 P28482 1/20 0.33
HDAC1 Q13547 1/20 0.33
HDAC2 Q92769 1/20 0.33
CCNE1 P24864 1/20 0.33
CDK2 P24941 1/20 0.33
CDK5 Q00535 1/20 0.33
HCAR2 Q8TDS4 1/20 0.32
HPGD P15428 2/20 0.32
GRIN1 Q05586 2/20 0.32
GRIN2A Q12879 2/20 0.32
GRIN2B Q13224 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21229056 0.83 NAMPT (0.38) HDAC6SMN1; SMN2CYP1A2CYP2D6CYP2C9
SCHEMBL20659199 0.81 SMN1; SMN2 (0.45) SMN1; SMN2CYP1A2CYP2C9CYP2C19
SCHEMBL5653620 0.81 SMN1; SMN2 (0.53) HDAC6SMN1; SMN2CYP1A2CYP2D6CYP2C9
SCHEMBL25282343 0.80 HDAC6 (0.42) FPR2FPR3HDAC6CYP1A2CYP2C19
SCHEMBL21229129 0.78 NAMPT (0.44) HDAC6HDAC1HDAC2
SCHEMBL18209793 0.76 L3MBTL1 (0.41) FPR2FPR3HTT
SCHEMBL21229124 0.75 HCAR2 (0.40) FPR2HDAC6SMN1; SMN2HCAR2HPGD
SCHEMBL21229053 0.75 HDAC1 (0.51) HDAC6SMN1; SMN2CYP1A2HDAC1HDAC2
SCHEMBL27719736 0.75 SMN1; SMN2 (0.38) FPR2SMN1; SMN2TSHRCCNE1CDK2
Bicarbonate SCHEMBL27848216 0.73 CCNE1 (0.45) SMN1; SMN2MAPK1HDAC1HDAC2CCNE1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-107580595-B Heterocyclic compounds and their use in the prevention or treatment of bacterial infections 拜欧蒂姆公司 2020-09-18 CN disclosed
EP-2427191-A1 PESTICIDAL COMPOSITIONS Dow AgroSciences LLC (US) 2012-03-14 EP disclosed
WO-2010129497-A1 PESTICIDAL COMPOSITIONS DOW AGROSCIENCES LLC (US) 2010-11-11 WO disclosed
EP-1446403-B1 ARYL SUBSTITUTED OXAZOLIDINONES WITH ANTIBACTERIAL ACTIVITY ASTRAZENECA AB (SE) 2006-04-12 EP disclosed
US-20050043374-A1 Aryl substituted oxazolidinones with antibacterial activity ASTRAZENECA AB (SE) 2005-02-24 US disclosed
EP-1446403-A1 ARYL SUBSTITUTED OXAZOLIDINONES WITH ANTIBACTERIAL ACTIVITY AstraZeneca AB (SE) 2004-08-18 EP disclosed
WO-2003035648-A1 ARYL SUBSTITUTED OXAZOLIDINONES WITH ANTIBACTERIAL ACTIVITY ASTRAZENECA AB (SE) 2003-05-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050043374-A1 Aryl substituted oxazolidinones with antibacterial activity HRH2, HDHD5, HRH1 FPR2 671/4885FPR3 1216/4885HDAC6 485/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.